The Combined Assessment of CTC and <i>ESR1</i> Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer.

ABSTRACT: Monitoring of metastatic breast cancer (mBC) is an important issue in the clinical management of patients. Liquid biopsy has become a non-invasive method for detecting and monitoring cancer in body fluids. The presence of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in peripheral blood indicates poor prognosis and may contribute to early detection of progression, but assessment of these levels is still not routine clinical management. The main objective of this study was to estimate the frequency and clinical value of the ESR1 and PIK3CA mutations identified in circulating free DNA (cfDNA.) The second goal was to evaluate whether simultaneous evaluation of CTCs and mutation status in cfDNA increases the prognostic value of liquid biopsy. The results of the

SUBMITTER: Szostakowska-Rodzos M 

PROVIDER: S-EPMC11900918 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature